ImageneBio is quoted at $5.71 as of April 25, 2026, recording 2.56% down for the day. Market-implied stability metrics indicate that ImageneBio has a high probability of financial distress over the coming years. Over the last 90 trading days, it has delivered negative risk-adjusted returns. ImageneBio symbol was changed from IKNA on 28th of July 2025. The performance scores are measured across the period from January 25, 2026 to April 25, 2026. Learn more.
ImageneBio (IMA) is listed on NASDAQ Exchange in USA. ImageneBio was previously known as IKNA Old and was traded on NASDAQ Exchange under the symbol IKNA. ImageneBio operates in the Biotechnology space. The company runs in the Biotechnology sector. ImageneBio now stands at 65.54 M in market capitalization, which maps the company to the micro-cap universe of biotechnology companies. The current market cap profile is reinforced by a workforce of about 15 people and about 11.18 M shares outstanding. The company has 387.03 K shares sold short (10.26 days to cover). ImageneBio operates as a research-driven pharmaceutical developer where revenue is driven by drug pipeline progression, regulatory approvals, and patent-protected sales. ImageneBio has $9.99 M in debt. ImageneBio financial stability analysisOwnership Allocation Over half of ImageneBio's outstanding shares are owned by institutional investors. Institutional holders such as large asset managers and pension funds typically maintain these positions as part of broader diversified mandates rather than concentrated bets on any single company. Their buying and selling activity, disclosed through 13F filings, can be a useful signal for tracking changes in professional sentiment toward ImageneBio.
Check ImageneBio Ownership DetailsESG Sustainability
ImageneBio's financial profile includes an ESG Environmental Score of 57.66, an ESG Governance Score of 60.59, and an ESG Social Score of 64.40. ESG metrics place ImageneBio above the median range within Biotechnology. Social responsibility and governance discipline are often incorporated into valuation frameworks. Certain developments may influence governance-related evaluations. The dataset reflects available ESG reporting.
ImageneBio's financial profile includes a Gross Profit Margin of -28.0%, an Operating Margin of -6056.4%, and a Return On Capital Employed of -36.0%. ImageneBio financial framework combines liquidity support with pressured financial positioning. Profitability remains under pressure, with return on assets below breakeven in the current period.
Debt LevelsImageneBio's financial profile includes $0.50 in Net Debt To EBITDA, a Debt To Equity of 0.08x, and a Long Term Debt To Capitalization of 5.5%. Supporting metrics include -$26.2 million in Net Debt and $6.0 million in Short Long Term Debt, which analysts use to evaluate ImageneBio's operational efficiency.
Current Assets
ImageneBio's financial profile includes $162.5 million in Total Assets, a Return On Tangible Assets of -31.0%, and a Debt To Assets of 6.2%. Supporting metrics include $9.3 million in Non Current Assets Total, which analysts use to evaluate ImageneBio's operational efficiency.
The stock is undergoing the symbol change. ImageneBio symbol was changed from IKNA on 28th of July 2025. ImageneBio trades publicly on the NASDAQ Exchange. ImageneBio employs 15 people. Headquarters are in 12526 High Bluff Drive, San Diego, CA, United States, 92130. Current valuation profile shows market cap 65.54 M, P/B 0.49, P/S 81.93. ImageneBio operates in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Financial reporting is combined with risk and trading context. The company is currently operating at a loss.
Methodology
Unless otherwise specified, financial data for ImageneBio is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. ImageneBio (USA Stocks:IMA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: Information for ImageneBio is compiled from public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Reporting latency may occur in some cases. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
ImageneBio has active sell-side coverage. Source-validated coverage currently shows 3 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 1 analyst has submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Stifel, J.P. Morgan, Bernstein Research, UBS Investment Research, Oppenheimer & Co., among others. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors